Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent"), a technology-based company with a well-established laboratory services ...

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...

Co-Diagnostics receives Australian patent covering Co-Dx PCR platform technologies for nucleic acid detection and analysis: Salt Lake City Wednesday, December 31, 2025, 11:00 Hrs ...

A 2022 study estimates that at-home flu tests have a sensitivity of about 63% if the test is performed within 72 hours of ...

WHO noted that prequalified tests can now be prioritized in pooled procurement mechanisms, which help lower prices, stabilize ...

In this interview, Dr. Gary Pestano and Dr. Prithwish Pal discuss the advantages ddPCR offers in molecular residual disease ...

Fulgent is set to buy Bako Diagnostics assets and StrataDx for $55.5M, expanding into anatomic pathology and dermatopathology to scale lab services.

From respiratory infection to fatal neurological disease, EHV-1 demands rapid PCR diagnosis, and detection protocols impact ...

Northwestern scientists have created the fastest-ever hepatitis C diagnostic, delivering accurate results in only 15 minutes. The test uses the DASH rapid PCR system, originally developed for COVID, ...

CoDiagnostics secures its first patent for the Co-Dx PCR platform in Australia, strengthening IP protection as the point-of-care system awaits regulatory clearance.

Roche’s cobas BV/CV assay gains CE Mark, enabling accurate, rapid diagnosis of bacterial vaginosis and candida vaginitis.

WHO said the decision builds on earlier emergency approvals and reflects the continued need for affordable, fast COVID-19 testing even after the pandemic’s emergency phase.